Neffy versus intramuscular epinephrine for allergic reactions after food challenge or immunotherapy
Official title: A Phase IV Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Run by ARS Pharmaceuticals, Inc. · NCT06834165 · Data updated 2026-11-12
This trial will test whether Neffy or standard intramuscular epinephrine works and is safe for people aged 4 and up who have allergic reactions during oral food challenges or allergen immunotherapy.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 4 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | ARS Pharmaceuticals, Inc. Industry-sponsored |
| Drugs / interventions | Immunotherapy |
| Locations | 6 sites (La Jolla, California and 5 other locations) |
| Status | Recruiting |
| Started | May 20, 2025 |
| Main results expected | April 2027 |
| Study ends | June 2027 |
| Registry record updated | April 21, 2026 |
| Trial ID | NCT06834165 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 4 years or older, weighing at least 15 kg, who are scheduled for an oral food challenge, allergen immunotherapy, or other allergy challenge and who experience a reaction judged to require epinephrine.
✕Probably not a fit
Patients with medical conditions that make epinephrine unsafe, those not undergoing a qualifying challenge, or those who do not experience a reaction are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 4 interventional study conducted at multiple U.S. centers enrolling patients age 4 and older who are scheduled for oral food challenges, allergen immunotherapy, or similar allergy challenges. If a participant has an allergic reaction that, in the investigator's opinion, requires epinephrine, they will be treated with either Neffy or intramuscular adrenaline according to the study protocol and monitored closely. Study staff will record symptom resolution, need for additional doses, vital signs, and any adverse events, with follow-up safety assessments after the event. The main focus is to characterize the safety and clinical response of Neffy compared with intramuscular adrenaline in these real-world challenge situations.
Why it matters
Potential benefit: If successful, the trial could support a needle-free epinephrine option that works as well as intramuscular adrenaline for treating reactions during challenges.
How similar studies have gone: Needle-free and intranasal epinephrine approaches have shown promising results in prior studies but are not yet as established as standard intramuscular epinephrine.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Is a patient 4 years old or greater, inclusive, who are scheduled to undergo OFC, AIT, or other relevant allergy challenge. * Has body weight 15 kg or greater at the time of allergy challenge. * Is willing and able to provide written informed consent prior to participating in the study. In the case of minors (\<18 years old), assent can be obtained from his/her legal representative, and as much possible from the patient himself/herself. * Patient experiences an allergic reaction that, in the opinion of the Investigator, requires treatment with epinephrine via neffy or IM Adrenalin. Exclusion Criteria: \- Has any clinically significant medical condition that precludes treatment with epinephrine as assessed by the Investigator.
Where it's running
-
Orso Health, Inc.
La Jolla, California, United States Recruiting -
Children's National Hospital
Washington D.C., District of Columbia, United States Recruiting -
Endeavor Health
Glenview, Illinois, United States Recruiting -
University Of Michigan
Ann Arbor, Michigan, United States Recruiting -
Weill Cornell Medicine/NewYork Presbyterian Hospital
New York, New York, United States Recruiting -
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States Recruiting
Study contacts
- Study coordinator: Osnat Ehrman, MSc.
- Email: osnate@pacificlinkconsulting.com
- Phone: 952.334.5797
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
What the Mayo Clinic is learning from blood clot tests in allergic reactions
This study tests whether real-time blood clotting markers can help understand and predict the severity of allergic reactions and anaphylaxis in patients 12 and older.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.